Whijae Roh
0000-0002-7395-9939
Publication & Citation Trends
Publications
0 total
Real-world clinical multi-omics analyses reveal bifurcation of ER-independent and ER-dependent drug resistance to CDK4/6 inhibitors OA
Cited by 10
Semantic Scholar
Abstract A042: Real-world clinical multi-omics and AI/ML analyses reveal bifurcation of drug resistance mechanisms to CDK4/6 inhibitors
Cited by 0
Semantic Scholar
Abstract 7182: EZH2 inhibition as a therapeutic strategy for castration resistant prostate cancer in combination with AR-antagonist enzalutamide
Cited by 0
Semantic Scholar
Identification of breast cancer subtypes and drug response prediction through forward and reverse translation
Cited by 4
Semantic Scholar
Modulation of enhancer of zeste homolog 2 (EZH2) pharmacodynamic (PD) markers and tumor gene expression by mevrometostat in combination with enzalutamide in patients with castration-resistant prostate cancer (CRPC).
Cited by 0
Semantic Scholar
Protocol for assessing distances in pathway space for classifier feature sets from machine learning methods
Cited by 0
Semantic Scholar
Protocol for obtaining cancer type and subtype predictions using subSCOPE
Cited by 0
Semantic Scholar
CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety. OA
Cited by 37
Semantic Scholar
Abstract CT102: Exploring the tumor molecular landscape associated withTMPRSS2-ERG: A post hoc analysis from the phase 3 TALAPRO-2 study of first-line (1L) talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in metastatic castration-resistant prostate cancer (mCRPC)
Cited by 0
Semantic Scholar
Research Topics
RNA modifications and cancer
(44)
Ferroptosis and cancer prognosis
(35)
Cancer Genomics and Diagnostics
(28)
Lung Cancer Treatments and Mutations
(26)
Cancer Immunotherapy and Biomarkers
(22)
Affiliations
Broad Institute
The University of Texas MD Anderson Cancer Center
University of Pittsburgh
Pfizer (United States)
University of Michigan–Ann Arbor